Panacea Biotec Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Panacea Biotec Ltd is ₹ 364.1 as of 04 May 10:56 . The P/E Ratio of Panacea Biotec Ltd changed from 0.8 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Shukra Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Panacea Biotec Ltd changed from ₹ 1086 crore on March 2021 to ₹ 2699 crore on March 2025 . This represents a CAGR of 19.96% over 5 yearsThe Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Panacea Biotec Ltd for the Dec '25 is ₹ 170.24 crore as compare to the Sep '25 revenue of ₹ 150.23 crore. This represent the growth of 13.32% The revenue of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 39.95 crore as compare to the Sep '25 revenue of ₹ 7.59 crore. This represent the growth of 426.35% The ebitda of Panacea Biotec Ltd for the Dec '25 is ₹ 16.79 crore as compare to the Sep '25 ebitda of ₹ -8.69 crore. This represent the decline of -293% The ebitda of Shukra Pharmaceuticals Ltd for the Dec '25 is ₹ 27.95 crore as compare to the Sep '25 ebitda of ₹ 1.29 crore. This represent the growth of 2066% The net profit of Panacea Biotec Ltd changed from ₹ 4.44 crore to ₹ 3.89 crore over 7 quarters. This represents a CAGR of -7.28% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ 20.36 crore over 7 quarters. This represents a CAGR of 189.96% The Dividend Payout of Panacea Biotec Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Panacea Biotec Ltd

India's leading research-based health management company with established research, manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL), which was incorporated on February 2, 1984 under the name of Panacea Drug (P) Limited.
The name of the Company was changed to the present 'Panacea Biotec Limited' in 1993. A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The plant for vaccines production (Radicura Pharma) and pharmaceutical formulations plant (Panacea Drug P Ltd) at New Delhi were established during the year 1988 and 1989 respectively.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Panacea Biotec Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Panacea Biotec Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Panacea Biotec Ltd is 2,214 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,272 Cr

What are the key factors driving the stock performance of Panacea Biotec Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Panacea Biotec Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Panacea Biotec Ltd and Shukra Pharmaceuticals Ltd?

As of May 4, 2026, the Panacea Biotec Ltd stock price is INR ₹361.5. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹29.07.

How do dividend payouts of Panacea Biotec Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Panacea Biotec Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.